Digest Network Come funziona
Network
/
Società
Bo
Non verificato

Boehringer Ingelheim

Di cosa scriviamo

FarmaceuticaImpreseIndustriaMedicina Salute BenesserePubblicità/Marketing/Media/Comunicazione

5 comunicati stampa

Guarda tutti i comunicati
15/07/2026
Farmaceutica
Medicina Salute Benessere
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1.00
0
03/09/2025
Boehringer Ingelheim Launches Swine Vaccine With Advanced Protection Against Porcine Circovirus Type 2 in the United States
Fonte
Boehringer Ingelheim
Emittente
Business Wire
1.00
0
Press Release cover image
22/11/2024
Farmaceutica
Sanità
Economia
Start-up
Boehringer Ingelheim launches VETMEDIN® Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Fonte
Boehringer Ingelheim
Emittente
PR News Wire
1.00
0
07/10/2024
Farmaceutica
Medicina Salute Benessere
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1.00
0
16/09/2024
Farmaceutica
Medicina Salute Benessere
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Fonte
Boehringer Ingelheim
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0